Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are...
-
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief...
-
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a...
-
Staten Island, New York, July 03, 2025 (GLOBE NEWSWIRE) -- This Independence Day, while the nation celebrates its freedom, the Tunnel to Towers Foundation is delivering financial freedom to 25...
-
(IRVING, Texas), June 27, 2025 (GLOBE NEWSWIRE) -- CHRISTUS Health is recognized as one of the most socially responsible health care systems in the country, according to a new report released this...
-
St. Louis, MO, June 20, 2025 (GLOBE NEWSWIRE) -- Meeting Professionals International (MPI), the world’s largest meeting and event industry association, hosted its annual press conference today at...
-
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower...
-
WATERLOO, Ontario, June 10, 2025 (GLOBE NEWSWIRE) -- In response to recent devastating wildfire seasons in Alberta, a new tool is helping communities in the province determine, reduce and better...
-
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104...
-
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...